Exciting News from Lehigh Valley Topper Cancer Institute

Lehigh Valley Topper Cancer Institute Is Now Offering a Pioneering Rectal Cancer Trial

Bringing Together a Team of Highly Skilled Clinicians

Lehigh Valley Topper Cancer Institute (LVTCI), part of Lehigh Valley Health Network (LVHN), is elated to announce the commencement of a clinical trial for pancreatic cancer. This announcement marks LVTCI's addition to a distinguished group of networks and hospitals engaged in this innovative research. The trial's principal investigator, Dr. Suresh Nair, Chief Physician of LVTCI, is overseeing this groundbreaking initiative.

Collaboration for Innovation

Researchers from Harvard Medical School and the Dana-Farber Cancer Institute have spearheaded this pivotal clinical trial. LVHN's participation underscores its commitment to advancing cancer treatment and providing patients with access to cutting-edge therapies.

Providing Hope to Patients

This clinical trial offers new hope to patients battling rectal cancer. LVTCI's dedication to providing comprehensive and compassionate care drives their pursuit of novel treatment options. Patients enrolled in the trial will have access to personalized, state-of-the-art treatments.

Setting a New Standard

With the launch of this clinical trial, LVTCI reinforces its position as a regional leader in cancer care. Their commitment to collaboration and innovation sets a new standard for patient care and advances the fight against pancreatic cancer.

Availability for Patients

For more information about the clinical trial and eligibility criteria, interested individuals can contact Lehigh Valley Topper Cancer Institute at [insert contact information here].